2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid | 729613-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid
• 英文别名: 5,6,7,8-tetrahydro-carbazole-2-carboxylic acid；5,6,7,8-Tetrahydro-carbazol-2-carbonsaeure；6,7,8,9-tetrahydro-5H-carbazole-2-carboxylic acid
• CAS: 729613-71-2
• 化学式: C₁₃H₁₃NO₂
• mdl: MFCD07789147
• 分子量: 215.252
• InChiKey: PCWDMUSCUJPFII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid 在 palladium on activated charcoal 作用下， 反应 3.0h， 以10%的产率得到9H-咔唑-2-羧酸
  参考文献：
  名称：

  [EN] FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS
  [FR] CARBAZOLES FONCTIONNALISÉS ET SUBSTITUÉS UTILISÉS EN TANT QU'AGENTS ANTI-CANCÉREUX

  摘要：

  本发明涉及抗肌球蛋白化合物，其制备方法，以及利用本发明的化合物治疗或预防疾病或紊乱的方法，如增生性疾病（最好是癌症）。

  公开号：

  WO2016008010A1
• 作为产物：
  描述：

  3-cyclohexylidenehydrazino-benzoic acid 在 硫酸 作用下， 生成 2,3,4,9-tetrahydro-1H-carbazole-7-carboxylic acid 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Collar; Plant, Journal of the Chemical Society, 1926, p. 809

  摘要：

  DOI：

文献信息

• [EN] NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS<br/>[FR] NOUVEAUX DERIVES D'INDOLE UTILES COMME INHIBITEURS DE FABP-4
  申请人：BIOVITRUM AB

  公开号：WO2004063156A1

  公开（公告）日：2004-07-29

  The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4. The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4.

  本发明涉及新化合物（I），其中R0、R1、R2、R3、R4、R5、R6、R7、R8、A、B、n、X和Y如描述和权利要求中所定义；以及包含这些化合物的药物组合物，以及这些化合物在医学中的使用和用于制备作用于脂肪酸结合蛋白FABP-4的药物的方法。
• Acylguanidine derivative or salt thereof
  申请人：Astellas Pharma Inc.

  公开号：US08076348B2

  公开（公告）日：2011-12-13

  [Problem] To provide a compound which can be used in the prevention and/or treatment of diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in the treatment of irritable bowel syndrome (IBS) and/or prevention of migraine. [Means for Resolution] It was found that an acylguanidine derivative having a tricyclic structure or a pharmaceutically acceptable salt thereof has a strong antagonism to 5-HT2B receptor and 5-HT7 receptor. In addition, the compound of the present invention having antagonism to both of the receptors showed superior pharmacological action in comparison with the case of the single use of an antagonist selective for either one of the receptors. Based on the above, the compound of the present invention is useful in preventing and/or treating diseases in which 5-HT2B receptor and 5-HT7 receptor are concerned, particularly in treating irritable bowel syndrome (IBS) and/or preventing migraine.

  [问题] 提供一种可以用于预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病的化合物，特别是用于治疗肠易激综合征（IBS）和/或预防偏头痛。 [解决方法] 发现一种具有三环结构的酰基胍衍生物或其药学上可接受的盐具有对5-HT2B受体和5-HT7受体的强烈拮抗作用。此外，本发明的化合物具有对两种受体的拮抗作用，与单独使用选择性拮抗剂相比表现出卓越的药理作用。基于上述，本发明的化合物在预防和/或治疗与5-HT2B受体和5-HT7受体有关的疾病中特别有用，特别是在治疗肠易激综合征（IBS）和/或预防偏头痛方面。
• ACYLGUANIDINE DERIVATIVE
  申请人：Kinoyama Isao

  公开号：US20100324017A1

  公开（公告）日：2010-12-23

  An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia and the like, based on the 5-HT 5A receptor modulating action. It was confirmed that a compound characterized by a structure that a tricyclic hetero ring having a pyrrole ring at the center and guanidine are bonded via a carbonyl group has a potent 5-HT 5A receptor modulating action and an excellent pharmacological action based thereon, and thus, it was found that the compound can be an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, particularly for memory-related functional disorders such as cognitive impairments including dementia and schizophrenia, thereby completing the present invention.

  本发明的目的是提供一种基于5-HT5A受体调节作用的新型优良的治疗或预防痴呆症、精神分裂症等药剂。经证实，一种以三环杂环在中心具有吡咯环，并通过羰基结合了胍的结构特征化合物具有强效的5-HT5A受体调节作用和基于此的优良药理作用，因此，发现该化合物可以成为治疗或预防痴呆症、精神分裂症、躁郁症或注意力缺陷多动障碍等的优良药剂，特别是对于认知障碍包括痴呆症和精神分裂症等的记忆相关功能障碍，从而完成了本发明。
• EP2119704
  申请人：——

  公开号：——

  公开（公告）日：——
• 558. The preparation of tetrahydrocarbazoles from 2-chloro-cyclohexanone
  作者：Neil Campbell、E. B. McCall

  DOI：10.1039/jr9500002870

  日期：——